Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of Getagozumab in Healthy Volunteers

Trial Profile

A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of Getagozumab in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Getagozumab (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Gmax Biopharm
  • Most Recent Events

    • 28 Jun 2018 According to a Gmax Biopharm media release, data will be presented at the at the Pulmonary Hypertension Association (PHA) 2018 International PH Conference and Scientific Sessions.
    • 30 Jan 2018 New trial record
    • 16 Dec 2017 According to a Gmax Biopharm media release, the company today announced that it has initiated a phase 1 clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top